Case Commentary: Dual β-lactam as part of regimen to treat Mycobacterium abscessus lung disease
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.00585-24 ↗Kurz gefasst
Kommentar in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Christopher K Lippincott und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Mycobacterium abscessus, Mycobacterium Infections, Nontuberculous, Anti-Bacterial Agents, beta-Lactams. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Individuals with compromised lung function and immunity are susceptible to developing chronic Mycobacterium abscessus infection. Current treatment recommendations typically involve using one β-lactam antibiotic in combination with non-β-lactam antibiotics. However, a recent case study (B. Becken, K. M. Dousa, J. L. Johnson, S. M. Holland, and R. A. Bonomo, Antimicrob Agents Chemother 68:e00319-24, 2024, https://doi.org/10.1128/aac.00319-24 ) demonstrated successful treatment of chronic M. abscessus lung disease in a child using two β-lactam antibiotics simultaneously. This commentary reviews the emerging evidence and outstanding questions regarding dual β-lactam therapy for M. abscessus infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
- Center for Nontuberculous Mycobacteria and Bronchiectasis, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
ORCID-Profile: Gyanu Lamichhane
Zitieren
APA
Lippincott, C. K., & Lamichhane, G. (2024). Case Commentary: Dual β-lactam as part of regimen to treat Mycobacterium abscessus lung disease. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00585-24
Vancouver
Lippincott CK, Lamichhane G. Case Commentary: Dual β-lactam as part of regimen to treat Mycobacterium abscessus lung disease. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00585-24
BibTeX
@article{Lippincott2024,
author = {Lippincott, Christopher K and Lamichhane, Gyanu},
title = {Case Commentary: Dual β-lactam as part of regimen to treat Mycobacterium abscessus lung disease},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.00585-24}
}
EUVIMED